| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
| 29 Sep 2026 |
8-K: Completion of Acquisition or Disposition of Assets; Unregistered Sales of Equity Securities
At the effective time of the Merger (the “Effective Time”), each outstanding share of Mantle capital stock (other than shares held by Mantle as treasury shares, shares held by Lexeo or Merger Sub, and Dissenting Shares) was converted int... |
| 22 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition; Other Events
Finalized SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 in support of accelerated approval pathway; topline data expected in second half of 2027 |
| 29 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 25, 2026, Lexeo Therapeutics, Inc. (the “Company”) held its virtual 2026 Annual Meeting of Stockholders (the “Annual Meeting”) exclusively online via live webcast. The stockholders voted on the following proposals at the Annual M... |
| 15 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
Lexeo Therapeutics Corporate Overview June 2026 Exhibit 99.3 |
| 11 May 2026 |
8-K: Results of Operations and Financial Condition; Other Events
SUNRISE-FA2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026; Awaiting final FDA feedback |
| 30 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On April 28, 2026 (the “Appointment Date”), Dr. Laura Sepp-Lorenzino was appointed to the board of directors (the “Board”) of Lexeo Therapeutics, Inc. (the “Company”). Dr. Sepp-Lorenzino will serve as a director with a term of office exp... |
| 30 Mar 2026 |
8-K: Results of Operations and Financial Condition; Other Events
SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026 following |
| 05 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On January 30, 2026, Lexeo Therapeutics, Inc. (the “Company”) entered into a Transition and Consulting Agreement (the “Transition Agreement”) with Dr. Adler, effective February 1, 2026, pursuant to which Dr. Adler stepped down from his r... |
| 27 Jan 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On January 27, 2026, Lexeo Therapeutics, Inc. (the “Company”) announced that the Board of Directors of the Company (the “Board”) appointed Jose Manuel Otero, Ph.D., the Company’s current Chief Technical Officer, to serve as Chief Operati... |
| 12 Jan 2026 |
8-K: Regulation FD Disclosure; Other Events
LX2020 generally well tolerated across ten participants with no clinically significant complement activation |
| 05 Nov 2025 |
8-K: Results of Operations and Financial Condition
FDA open to pooling data from ongoing Phase I/II studies of LX2006 with data from pivotal trial, and to earlier |
| 17 Oct 2025 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +2 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of October 16, 2025, by and among Lexeo Therapeutics, Inc., a Delaware corporation (the “Company”), and the individuals and entities listed on Exhibit A attached to this A... |
| 07 Oct 2025 |
8-K: Regulation FD Disclosure; Other Events
Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy |
| 14 Aug 2025 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
Breakthrough Therapy designation granted for LX2006 based on interim data from Phase I/II trials demonstrating clinically meaningful improvements in cardiac and neurologic measures of Friedreich ataxia |
| 30 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 26, 2025, Lexeo Therapeutics, Inc. (the “Company”) held its virtual 2025 Annual Meeting of Stockholders (the “Annual Meeting”) exclusively online via live webcast. The stockholders voted on the following proposals at the Annual M... |
| 27 May 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of May 27, 2025, by and among Lexeo Therapeutics, Inc., a Delaware corporation (the “Company”), and the individuals and entities listed on Exhibit A attached to this Agree... |
| 12 May 2025 |
8-K: Results of Operations and Financial Condition
Announced positive interim data for LX2006 from Phase 1/2 studies in Friederich ataxia (FA) cardiomyopathy; frataxin expression and LVMI improvement exceeded co-primary target thresholds for planned registrational study |
| 07 Apr 2025 |
8-K: Regulation FD Disclosure; Other Events
Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study |
Loading...